Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.

dc.contributor.author

Wolfe, Cameron R

dc.contributor.author

Tomashek, Kay M

dc.contributor.author

Patterson, Thomas F

dc.contributor.author

Gomez, Carlos A

dc.contributor.author

Marconi, Vincent C

dc.contributor.author

Jain, Mamta K

dc.contributor.author

Yang, Otto O

dc.contributor.author

Paules, Catharine I

dc.contributor.author

Palacios, Guillermo M Ruiz

dc.contributor.author

Grossberg, Robert

dc.contributor.author

Harkins, Michelle S

dc.contributor.author

Mularski, Richard A

dc.contributor.author

Erdmann, Nathaniel

dc.contributor.author

Sandkovsky, Uriel

dc.contributor.author

Almasri, Eyad

dc.contributor.author

Pineda, Justino Regalado

dc.contributor.author

Dretler, Alexandra W

dc.contributor.author

de Castilla, Diego Lopez

dc.contributor.author

Branche, Angela R

dc.contributor.author

Park, Pauline K

dc.contributor.author

Mehta, Aneesh K

dc.contributor.author

Short, William R

dc.contributor.author

McLellan, Susan LF

dc.contributor.author

Kline, Susan

dc.contributor.author

Iovine, Nicole M

dc.contributor.author

El Sahly, Hana M

dc.contributor.author

Doernberg, Sarah B

dc.contributor.author

Oh, Myoung-Don

dc.contributor.author

Huprikar, Nikhil

dc.contributor.author

Hohmann, Elizabeth

dc.contributor.author

Kelley, Colleen F

dc.contributor.author

Holodniy, Mark

dc.contributor.author

Kim, Eu Suk

dc.contributor.author

Sweeney, Daniel A

dc.contributor.author

Finberg, Robert W

dc.contributor.author

Grimes, Kevin A

dc.contributor.author

Maves, Ryan C

dc.contributor.author

Ko, Emily R

dc.contributor.author

Engemann, John J

dc.contributor.author

Taylor, Barbara S

dc.contributor.author

Ponce, Philip O

dc.contributor.author

Larson, LuAnn

dc.contributor.author

Melendez, Dante Paolo

dc.contributor.author

Seibert, Allan M

dc.contributor.author

Rouphael, Nadine G

dc.contributor.author

Strebe, Joslyn

dc.contributor.author

Clark, Jesse L

dc.contributor.author

Julian, Kathleen G

dc.contributor.author

de Leon, Alfredo Ponce

dc.contributor.author

Cardoso, Anabela

dc.contributor.author

de Bono, Stephanie

dc.contributor.author

Atmar, Robert L

dc.contributor.author

Ganesan, Anuradha

dc.contributor.author

Ferreira, Jennifer L

dc.contributor.author

Green, Michelle

dc.contributor.author

Makowski, Mat

dc.contributor.author

Bonnett, Tyler

dc.contributor.author

Beresnev, Tatiana

dc.contributor.author

Ghazaryan, Varduhi

dc.contributor.author

Dempsey, Walla

dc.contributor.author

Nayak, Seema U

dc.contributor.author

Dodd, Lori E

dc.contributor.author

Beigel, John H

dc.contributor.author

Kalil, Andre C

dc.contributor.author

ACTT-4 Study Group

dc.date.accessioned

2022-07-24T17:36:14Z

dc.date.available

2022-07-24T17:36:14Z

dc.date.issued

2022-05-23

dc.date.updated

2022-07-24T17:36:13Z

dc.description.abstract

Background

Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.

Methods

In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), and Japan (one site). Hospitalised adults (≥18 years) with COVID-19 who required supplemental oxygen administered by low-flow (≤15 L/min), high-flow (>15 L/min), or non-invasive mechanical ventilation modalities who met the study eligibility criteria (male or non-pregnant female adults ≥18 years old with laboratory-confirmed SARS-CoV-2 infection) were enrolled in the study. Patients were randomly assigned (1:1) to receive either baricitinib, remdesivir, and placebo, or dexamethasone, remdesivir, and placebo using a permuted block design. Randomisation was stratified by study site and baseline ordinal score at enrolment. All patients received remdesivir (≤10 days) and either baricitinib (or matching oral placebo) for a maximum of 14 days or dexamethasone (or matching intravenous placebo) for a maximum of 10 days. The primary outcome was the difference in mechanical ventilation-free survival by day 29 between the two treatment groups in the modified intention-to-treat population. Safety analyses were done in the as-treated population, comprising all participants who received one dose of the study drug. The trial is registered with ClinicalTrials.gov, NCT04640168.

Findings

Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (49%) to dexamethasone plus remdesivir plus placebo. The mean age of the patients was 58·3 years (SD 14·0) and 590 (58%) of 1010 patients were male. 588 (58%) of 1010 patients were White, 188 (19%) were Black, 70 (7%) were Asian, and 18 (2%) were American Indian or Alaska Native. 347 (34%) of 1010 patients were Hispanic or Latino. Mechanical ventilation-free survival by day 29 was similar between the study groups (Kaplan-Meier estimates of 87·0% [95% CI 83·7 to 89·6] in the baricitinib plus remdesivir plus placebo group and 87·6% [84·2 to 90·3] in the dexamethasone plus remdesivir plus placebo group; risk difference 0·6 [95% CI -3·6 to 4·8]; p=0·91). The odds ratio for improved status in the dexamethasone plus remdesivir plus placebo group compared with the baricitinib plus remdesivir plus placebo group was 1·01 (95% CI 0·80 to 1·27). At least one adverse event occurred in 149 (30%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 179 (37%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·5% [1·6 to 13·3]; p=0·014). 21 (4%) of 503 patients in the baricitinib plus remdesivir plus placebo group had at least one treatment-related adverse event versus 49 (10%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 6·0% [2·8 to 9·3]; p=0·00041). Severe or life-threatening grade 3 or 4 adverse events occurred in 143 (28%) of 503 patients in the baricitinib plus remdesivir plus placebo group and 174 (36%) of 482 patients in the dexamethasone plus remdesivir plus placebo group (risk difference 7·7% [1·8 to 13·4]; p=0·012).

Interpretation

In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events, treatment-related adverse events, and severe or life-threatening adverse events. A more individually tailored choice of immunomodulation now appears possible, where side-effect profile, ease of administration, cost, and patient comorbidities can all be considered.

Funding

National Institute of Allergy and Infectious Diseases.
dc.identifier

S2213-2600(22)00088-1

dc.identifier.issn

2213-2600

dc.identifier.issn

2213-2619

dc.identifier.uri

https://hdl.handle.net/10161/25508

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

The Lancet. Respiratory medicine

dc.relation.isversionof

10.1016/s2213-2600(22)00088-1

dc.subject

ACTT-4 Study Group

dc.title

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.

dc.type

Journal article

duke.contributor.orcid

Wolfe, Cameron R|0000-0002-5365-5030

pubs.begin-page

S2213-2600(22)00088-1

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, General Internal Medicine

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Initiatives

pubs.organisational-group

Duke Science & Society

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4) a randomised, double-blind, double placebo-c.pdf
Size:
337.51 KB
Format:
Adobe Portable Document Format